TY  - JOUR 
AU  - Mendiburu-Eliçabe, Marina
AU  - García Sancha, Natalia
AU  - Corchado Cobos, Roberto
AU  - Martínez López, Angélica
AU  - Chang, Hang
AU  - Hua Mao, Jian
AU  - Blanco Gómez, Adrián
AU  - García Casas, Ana
AU  - Castellanos Martín, Andrés
AU  - Salvador, Nélida
AU  - Jiménez Navas, Alejandro
AU  - Pérez Baena, Manuel Jesús
AU  - Sánchez Martín, Manuel Adolfo
AU  - Abad Hernández, María Mar
AU  - Carmen, Sofía Del
AU  - Claros Ampuero, Juncal
AU  - Cruz Hernández, Juan Jesús
AU  - Rodríguez Sánchez, César Augusto
AU  - García Cenador, María Begoña
AU  - García Criado, Francisco Javier
AU  - Santamaría Vicente, Rodrigo
AU  - Castillo Lluva, Sonia
AU  - Pérez Losada, Jesús
PY  - 2024
SN  - 2001-1326
UR  - http://hdl.handle.net/10366/159536
AB  - [EN]Luminal A tumours generally have a favourable prognosis but possess the highest 10-year recurrence risk among breast cancers. Additionally, a quarter of the recurrence cases occur within 5 years post-diagnosis. Identifying such patients is crucial...
LA  - eng
PB  - Wiley (Commercial Publisher)
KW  - Breast cancer
KW  - Genetic signature
KW  - LASSO
KW  - Luminal A subtype
KW  - NCAPH
KW  - Prognosis
KW  - Relapse-free  survival
KW  - Breast Neoplasms
KW  - Prognosis
KW  - Gene Expression Profiling
KW  - Animals
KW  - Humans
KW  - Mice
KW  - Nuclear Proteins
KW  - Cell Cycle Proteins
TI  - NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
DO  - 10.1002/ctm2.1554
T2  - Clinical and Translational Medicine
VL  - 14
M2  - e1554
ER  -